DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
IRVINE, Calif., Feb. 18, 2016 -- Endologix, Inc. (NASDAQ:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2015 financial results, which will take place on Monday, February 22, 2016 after the close of the market.
Endologix will hold a conference call on Monday, February 22, 2016 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results. The dial-in numbers are (877) 407-0789 for domestic callers and (201) 689-8562 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.endologix.com.
After the live webcast, a replay of the webcast will remain available online from the investor relations page of Endologix's website, www.endologix.com, through February 22, 2017. In addition, a transcript will be posted to the website and a telephonic replay of the call will be available until February 29, 2016. The replay dial-in numbers are (877) 870-5176 for domestic callers and (858) 384-5517 for international callers. Please use the replay pin number 13629814.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.
ENDOLOGIX CONTACT: Endologix, Inc. John McDermott, CEO Vaseem Mahboob, CFO (949) 595-7200 www.endologix.com INVESTOR CONTACTS: The Ruth Group Nick Laudico (646) 536-7030 Zack Kubow (646) 536-7020
